2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
14
Lung Neoplasms
11
Breast Neoplasms
9
Colorectal Neoplasms
8
Prostatic Neoplasms
7
Stomach Neoplasms
3
Rectal Neoplasms
3
Polycystic Ovary Syndrome
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Smoking Cessation
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic cancer, adult
2
Ovarian Neoplasms
2
Neoplastic Cells, Circulating
2
Motor Activity
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Endometrial Neoplasms
2
Disease
2
Wilms Tumor
1
Venous Thromboembolism
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Testicular Germ Cell Tumor
1
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Hematologic Tests
×
Clear all
NCT04566029
2025-12-10
AMI
Centre Hospitalier Universitaire de NÄ«mes
Completed
40 enrolled